Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of concomitant use of doxifluridine, radiotherapy and immunotherapy in patients with advanced cervical cancer
Autore:
Yamamoto, K; Noda, K; Hatae, M; Kudo, T; Hasegawa, K; Nishimura, R; Honjo, H; Yajima, A; Sato, S; Mizutani, K; Yakushiji, M; Terashima, Y; Ochiai, K; Sasaki, H; Ozaki, M;
Indirizzi:
Kinki Univ, Sch Med, Dept Obstet & Gynecol, Osaka 5898511, Japan Kinki Univ Osaka Japan 5898511 pt Obstet & Gynecol, Osaka 5898511, Japan Kagoshima City Hosp, Dept Obstet & Gynecol, Kagoshima 8928580, Japan Kagoshima City Hosp Kagoshima Japan 8928580 ol, Kagoshima 8928580, Japan Okayama Univ, Sch Med, Dept Obstet & Gynecol, Okayama 7000914, Japan Okayama Univ Okayama Japan 7000914 tet & Gynecol, Okayama 7000914, Japan Hyogo Med Ctr Adults, Dept Obstet & Gynecol, Akashi, Hyogo 6730021, Japan Hyogo Med Ctr Adults Akashi Hyogo Japan 6730021 shi, Hyogo 6730021, Japan Kyoto Prefectural Univ, Sch Med, Dept Obstet & Gynecol, Kamigyo Ku, Kyoto 6020841, Japan Kyoto Prefectural Univ Kyoto Japan 6020841 igyo Ku, Kyoto 6020841, Japan Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Aoba Ku, Sendai, Miyagi 9808574, Japan Tohoku Univ Sendai Miyagi Japan 9808574 Ku, Sendai, Miyagi 9808574, Japan Tokyo Metropolitan Komagome Hosp, Dept Obstet & Gynecol, Bunkyo Ku, Tokyo 1130021, Japan Tokyo Metropolitan Komagome Hosp Tokyo Japan 1130021 okyo 1130021, Japan Kurume Univ, Fac Med, Dept Obstet & Gynecol, Fukuoka 8300011, Japan KurumeUniv Fukuoka Japan 8300011 stet & Gynecol, Fukuoka 8300011, Japan Jikei Univ, Sch Med, Dept Obstet & Gynecol, Minato Ku, Tokyo 1050003, Japan Jikei Univ Tokyo Japan 1050003 Gynecol, Minato Ku, Tokyo 1050003, Japan Belland Hosp, Dept Obstet & Gynecol, Osaka 5998247, Japan Belland Hosp Osaka Japan 5998247 Obstet & Gynecol, Osaka 5998247, Japan
Titolo Testata:
ONCOLOGY REPORTS
fascicolo: 2, volume: 8, anno: 2001,
pagine: 273 - 277
SICI:
1021-335X(200103/04)8:2<273:EOCUOD>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
THYMIDINE PHOSPHORYLASE; TUMOR-CELLS; 5'-DEOXY-5-FLUOROURIDINE; 5-FLUOROURACIL; CHEMOTHERAPY; CAPECITABINE; COMBINATION; IRRADIATION; XENOGRAFTS; EFFICACY;
Keywords:
doxifluridine; sizofilan; response rate; radiation therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Yamamoto, K Kinki Univ, Sch Med, Sakai Hosp, Dept Obstet & Gynecol, 2-7-1 Harayamadai,Osaka 5900132, Japan Kinki Univ 2-7-1 Harayamadai Osaka Japan 5900132 00132, Japan
Citazione:
K. Yamamoto et al., "Effects of concomitant use of doxifluridine, radiotherapy and immunotherapy in patients with advanced cervical cancer", ONCOL REP, 8(2), 2001, pp. 273-277

Abstract

Clinical effects of doxifluridine (group A, 600 mg/ body/day; group B, 800mg/body/day) combined with radiotherapy and immunotherapy were evaluated in patients with advanced cancer of the uterine cervix. Response rates were 84.2% (16/19 patients) in group A and 100% (18/18 patients) in group B, respectively (p=0.230). There was no significant difference in adverse reaction incidence between the methods but significantly higher grade adverse reaction were observed in group B than in group A (p=0.048). Time to progression (TTP) was longer in group B than in group A (p=0.081). The optimal 5'-DFUR dose was 800 mg/body (group B), by which higher grade adverse reactions were fully controlled and TTP was prolonged.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/07/20 alle ore 23:54:40